Mifepristone and Misoprostol for Early Pregnancy Loss and Medication Abortion

被引:5
作者
Macnaughton, Honor [1 ,2 ]
Nothnagle, Melissa [3 ,4 ]
Early, Jessica [1 ,2 ]
机构
[1] Tufts Univ, Family Med Residency, Cambridge Hlth Alliance, Malden, MA USA
[2] Tufts Univ, Sch Med, Dept Family Med, Boston, MA 02111 USA
[3] Natividad Family Med Residency, Salinas, CA USA
[4] Univ Calif San Francisco, Sch Med, Dept Family & Community Med, San Francisco, CA USA
关键词
VAGINAL MISOPROSTOL; MANAGEMENT; ALTERNATIVES; ULTRASOUND; IMMEDIATE; EFFICACY; HEALTH;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Medication regimens using mifepristone and misoprostol are safe and effective for outpatient treatment of early pregnancy loss for up to 84 days' gestation and for medication abortion up to 77 days' gestation. Gestational age is determined using ultrasonography or menstrual history. Ultrasonography is needed when gestational dating cannot be confirmed using clinical data alone or when there are risk factors for ectopic pregnancy. The most effective regimens for medication management of early pregnancy loss and medication abortion include 200 mg of oral mifepristone (a progesterone receptor antagonist) followed by 800 mcg of misoprostol (a prostaglandin El analogue) administered buccally or vaginally. Cramping and bleeding are expected effects of the medications, with bleeding lasting an average of nine to 16 days. The adverse effects of misoprostol (e.g., low-grade fever, gastrointestinal symptoms) can be managed with nonsteroidal anti-inflammatory drugs or antiemetics. Ongoing pregnancy, infection, hemorrhage, undiagnosed ectopic pregnancy, and the need for unplanned uterine aspiration are rare complications. Clinical history, combined with serial quantitative beta human chorionic gonadotropin levels, urine pregnancy testing, or ultrasonography, is used to establish complete passage of the pregnancy tissue.
引用
收藏
页码:473 / 480
页数:8
相关论文
共 38 条
[1]  
[Anonymous], 2013, Obstet Gynecol, V121, P411, DOI 10.1097/01.AOG.0000426427.79586.3b
[2]   Prevention of infection after induced abortion [J].
不详 .
CONTRACEPTION, 2011, 83 (04) :295-309
[3]  
[Anonymous], DAILYMED
[4]   Women's Mental Health and Well-being 5 Years After Receiving or Being Denied an Abortion A Prospective, Longitudinal Cohort Study [J].
Biggs, M. Antonia ;
Upadhyay, Ushma D. ;
McCulloch, Charles E. ;
Foster, Diana G. .
JAMA PSYCHIATRY, 2017, 74 (02) :169-178
[5]   Alternatives to routine ultrasound for eligibility assessment prior to early termination of pregnancy with mifepristone-misoprostol [J].
Bracken, H. ;
Clark, W. ;
Lichtenberg, E. S. ;
Schweikert, S. M. ;
Tanenhaus, J. ;
Barajas, A. ;
Alpert, L. ;
Winikoff, B. .
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2011, 118 (01) :17-23
[6]   Mifepristone With Buccal Misoprostol for Medical Abortion A Systematic Review [J].
Chen, Melissa J. ;
Creinin, Mitchell D. .
OBSTETRICS AND GYNECOLOGY, 2015, 126 (01) :12-21
[7]   Medication abortion employing routine sequential measurements of serum hCG and sonography only when indicated [J].
Clark, Wesley ;
Panton, Tanya ;
Hann, Louisa ;
Gold, Marji .
CONTRACEPTION, 2007, 75 (02) :131-135
[8]   Mifepristone and misoprostol administered simultaneously versus 24 hours apart for abortion - A Randomized controlled trial [J].
Creinin, Mitchell D. ;
Schreiber, Courtney A. ;
Bednarek, Paula ;
Lintu, Hanna ;
Wagner, Marie-Soleil ;
Meyn, Leslie A. .
OBSTETRICS AND GYNECOLOGY, 2007, 109 (04) :885-894
[9]  
Danco, 2016, PAT AGR FORM MIF TAB
[10]   A repeat dose of misoprostol 800 mcg following mifepristone for outpatient medical abortion at 64-70 and 71-77 days of gestation: A retrospective chart review [J].
Dzuba, Ilana G. ;
Castillo, Philicia W. ;
Bousieguez, Manuel ;
Lugo Hernandez, Elba Margarita ;
Castaneda Vivar, Jose Juan ;
Sanhueza Smith, Patricio .
CONTRACEPTION, 2020, 102 (02) :104-108